FDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
Foundation Medicine's FoundationOne Liquid CDx just became the first FDA-approved companion diagnostic for WILSERDLY (giredestrant) plus everolimus in ESR1-mutated advanced breast cancer. The blood-based test, already covered by Medicare for advanced cancer patients, gives doctors a single-draw way to spot who might qualify for Genentech's next-gen therapy.
- 2 sources report it: aol.com, finance.yahoo.com.
- The source published it on Nov 16, 2026 at 3:15 PM.
Nothing open. Every check passed.
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for WILSERDLY (giredestrant) when it's used alongside everolimus, Foundation Medicine announced Monday. It's the first FDA-approved companion diagnostic for that pairing, and Medicare covers the test for patients with advanced cancer. The blood-based panel is designed to flag patients whose tumors carry ESR1 mutations and who may be eligible for the combination.
WILSERDLY is an estrogen receptor antagonist cleared with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test. The indication covers patients whose disease came back during or after endocrine-based adjuvant therapy, or whose cancer progressed on at least one endocrine-based regimen in the metastatic setting.
The numbers behind the approval are stark. ER-positive, HER2-negative disease makes up roughly 70% of breast cancer cases, and acquired ESR1 mutations can drive resistance to endocrine therapies, particularly after CDK inhibitors. In that post-CDK inhibitor setting, up to 40% of people with ER-positive, HER2-negative disease carry ESR1 mutations.
Foundation Medicine now holds nine FDA-approved companion diagnostic indications for breast cancer — more than any other comprehensive genomic profiling company — and more than 100 approved companion diagnostic indications globally. FoundationOne Liquid CDx analyzes 324 genes from circulating cell-free DNA and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes.
Vera Grossmann, Foundation Medicine's interim chief executive officer and chief operating officer, said biomarker testing at recurrence is critical because breast cancer can mutate and resist early treatments, adding that the test has the sensitivity to detect ESR1 and find patients likely to benefit most from Genentech's next-generation SERD combination therapy. Jean A. Sachs, chief executive officer at Living Beyond Breast Cancer, said learning a metastatic treatment has stopped working brings fear and uncertainty, and welcomed a new therapy option plus a high-quality companion diagnostic to identify who might be a good fit.
TopicsFoundation Medicine · FoundationOne Liquid CDx · WILSERDLY · giredestrant · everolimus · Genentech · FDA · Living Beyond Breast Cancer
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status
- Health & science statnews.com 1 viewFDA approves Roche's Wilserdly for resistant breast cancer

